Investing.com - Financial Markets Worldwide

UPDATE 1-Eli Lilly to supply 26,000 doses of COVID-19 antibody drug to Canada

Published 2020-11-24, 01:40 p/m
LLY
-

(Adds details on the deal, background)

Nov 24 (Reuters) - Eli Lilly (NYSE:LLY) and Co LLY.N said on Tuesday it has signed an agreement with the Canadian government to supply 26,000 doses of its antibody drug to treat COVID-19 patients for $32.5 million.

The treatment, bamlanivimab, which was developed in partnership with Canadian biotech company AbCellera, will be supplied to Canada over a three-month period between December and February. drugmaker said additional doses will be supplied to Canada on a monthly basis according to the medical need of the country and the availability of supply.

Last week, Canada granted an interim authorization to bamlanivimab for treating COVID-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.